Boston Scientific
VC Fund
Marlborough, United States
Boston Scientific is an innovator of medical solutions that improve the health of patients around the world. Boston Scientific's products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. BostonScientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies, and services across a wide range of medical specialties. These less-invasive medical technologies provide alternatives to major surgery and other medical procedures that are typically traumatic to the body. In less-invasive procedures, devices are usually inserted into the body through natural openings or small incisions and can be guided to most areas of the anatomy to diagnose and treat a wide range of medical problems. Boston Scientific continues to innovate in these areas and is extending its innovations into new geographies and high-growth adjacency markets. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Boston Scientific acts with integrity and compassion to support patients, customers, our communities, and each other.
- Total investments:
- 54
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries Boston Scientific invests in
Stages Boston Scientific invests in
Countries Boston Scientific invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $3M–$36M
- Series C
- $6M–$27M
- Series D
- $8.3M–$175M
Investment Focus
Industry
- Health Care 34 (63%)
- Medical Device 31 (57%)
- Biotechnology 19 (35%)
- Medical 14 (26%)
- Therapeutics 8 (15%)
Stage
- Series B 10 (19%)
- Series C 10 (19%)
- Series D 9 (17%)
- Funding Round 8 (15%)
- Series A 4 (7%)
Country
- United States 32 (59%)
- Israel 3 (6%)
- Canada 1 (2%)
- Australia 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexander Weir
Business Development Manager
|
Business Development Manager | Total investments: 0 | Find email | |
Douglas J. Duchon
Sr. Program Manager
|
Sr. Program Manager | Total investments: 0 | Find email | |
Eric Thepaut
Executive Vice President, President EMEA
|
Executive Vice President, President EMEA | Total investments: 0 | Find email | |
Ian T. Meredith
Executive Vice President and Global Chief Medical Officer
|
Executive Vice President and Global Chief Medical Officer | Total investments: 0 | Find email | |
Isaac Knoot
Vice President, US Sales Enablement
|
Vice President, US Sales Enablement | Total investments: 0 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MiRus
|
MiRus is a medical device company focused on designing innovative solutions for the treatment of spinal and orthopedic degeneration and deformities. | $1.5B / Corporate Round / May 18, 2026 | |
Anumana
|
Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing tools that assist healthcare professionals in identifying potential heart issues. Anumana's platform extends beyond diagnostics, aiming to improvepatient outcomes throughout the entire continuum of cardiovascular care, including perioperative and acute settings. By utilizing machine learning techniques, Anumana aims to refine screening processes, making it easier for clinicians to detect heart diseases and intervene promptly. This approach contributes to more efficient healthcare delivery and better management of cardiovascular health. | Series C / Apr 24, 2025 | |
4C Medical Technologies
|
4C Medical Technologies is a medical device company that develops minimally invasive therapies for structural heart disease. It preserves the native mitral valve and left ventricle, eliminating known issues associated with transcatheter mitral valve replacement technologies that rely on placement and fixation in the native mitral annulus and leftventricle. | $175M / Series D / Mar 05, 2025 | |
Nectero Medical
|
Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. The company was founded in 2017 and is headquartered in Dover, Delaware, United States. | $96M / Series D / Apr 11, 2024 | |
SetPoint Medical
|
SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $80M / Jan 19, 2023 | |
|
Nectero Medical
|
Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. The company was founded in 2017 and is headquartered in Dover, Delaware, United States. | $19.5M / Series C / Sep 10, 2021 | |
Append Medical
|
Append Medical develops a next-generation transcatheter Left Atrial Appendage (LAA) closure system.The Append Medical solution is in the pre-clinical in-vivo trial phase. It is intended to become a differentiated solution in the LAA closure market, which has been estimated to reach $25B within several years. This is the second-fastest growingsegment of the medical device market, with potential sales of $500M in 2019. Append Medical is a member of MEDX Xelerator, a medtech incubator backed by Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center. | $7.4M / Series A / Aug 04, 2021 | |
|
SetPoint Medical
|
SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $64M / Jan 27, 2021 | |
Preventice Solutions
|
Preventice Solutions is a privately-held company that offers a portfolio of mobile cardiac health solutions and services. It is a developer of mobile health solutions and remote monitoring services, connecting patients, clinicians, and hospitals. | $137M / Series B / Jul 15, 2020 | |
|
SetPoint Medical
|
SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $15.7M / Sep 18, 2019 | |
| See all 54 investments → | |||
Co-Investors
Action Potential Venture Capital
6 deals together
Morgenthaler Ventures
6 deals together
New Enterprise Associates
5 deals together
Aperture Venture Partners
4 deals together
Domain Associates
4 deals together
ONSET Ventures
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Boston Scientific invest in?
Boston Scientific invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series B and Series C stage. Most of the 54 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Boston Scientific's check size?
Boston Scientific typically joins rounds of $3M–$36M at Series B, $6M–$27M at Series C and $8.3M–$175M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Boston Scientific participates in.
How do I contact Boston Scientific?
Public channels for Boston Scientific include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Boston Scientific?
The team at Boston Scientific includes Alexander Weir (Business Development Manager), Douglas J. Duchon (Sr. Program Manager) and Eric Thepaut (Executive Vice President, President EMEA), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
